Leydig stem cells and future therapies for hypogonadism

Area of Science:

• Reproductive biology
• Stem cell therapy
• Endocrinology

Background:

• Hypogonadism is a condition characterized by the failure of the testes to produce or develop normally, leading to testosterone deficiency.
• Leydig stem cells (LSCs) are crucial for testosterone production.
• Current treatments for hypogonadism often involve testosterone replacement therapy, which can have side effects.

Purpose of the Study:

• To review recent advances in Leydig stem cell (LSC) development.
• To summarize current and emerging treatments for hypogonadism.

Main Methods:

• In-vitro and in-vivo studies on inducing stem cell differentiation into Leydig cells.
• Assessment of LSC grafting with Sertoli cells.
• Review of novel testosterone delivery systems and selective receptor modulators.

Main Results:

• Stem cells can be induced to differentiate into testosterone-producing Leydig cells.
• LSC grafting with Sertoli cells increases testosterone levels with minimal impact on gonadotropins.
• New intranasal and oral testosterone agents show promise for treating hypogonadism while preserving fertility.

Conclusions:

• LSC therapies offer an effective approach to increase testosterone levels without adverse effects on gonadotropins.
• Further research is needed to evaluate LSC grafting efficacy in human trials.
• Novel therapies like enclomiphene citrate and selective androgen receptor modulators require additional study for safety and efficacy.